Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
Blanchet
P J
PJ
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke Bethesda, Maryland, USA.
Metman
L V
LV
Mouradian
M M
MM
Chase
T N
TN
D003917:Dextrorphan / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D009069:Movement Disorders / Q000150:complications* / Q000188:drug therapy*; D010300:Parkinson Disease / Q000150:complications*; D010919:Placebos; D012720:Severity of Illness Index
D018691:Excitatory Amino Acid Antagonists; D010919:Placebos; D003917:Dextrorphan; D007980:Levodopa